Topics

Astrocytoma | Treatment | Immunotherapy | Vaccines

Home > Publications > Topics > Astrocytoma > Treatment > Immunotherapy > Vaccines

Hashii Y, Fujisaki H, Terashima K, Goto H, Horibe K, Sugiyama K, Takahara-Matsubara M, Goto M, Yanagisawa T, Kikuta A, Kawamoto H, Hashimoto N, Oka Y, Sugiyama H, Hara J.
Phase 1/2 study of a WT1 peptide-dosing emulsion in pediatric patients with recurrent/refractory diffuse intrinsic pontine glioma, glioblastoma, or anaplastic astrocytoma.
Eur J Cancer. 2026 May 19;242:116808. doi: 10.1016/j.ejca.2026.116808. PMID: 42176363. Trial registration ID: NCT02750891˰ ˍ

Bunse L, Lindner K, Wick A, Freitag A, Lanz LM, Edelmann D, Suwala A, Breckwoldt MO, Harting I, Sahm F, Schlenk RF, Schmitt A, Schnell O, Hense J, Misch M, Krex D, Denk M, Walz J, Steinbach JP, von Deimling A, Schmitt M, Bunse T, Tabatabai G, Bendszus M, Poschke I, Wick W, Platten M.
IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.
Nat Cancer. 2026 Jul 1. doi: 10.1038/s43018-026-01199-y. PMID: 42387024. Trial registration ID: NCT02454634. ˍ

Nakata J, Nakamura N, Motooka D, Yokota C, Hayashi Y, Hirayama R, Fujiki F, Morimoto S, Umehara T, Nakajima H, Oji Y, Tsuboi A, Oka Y, Kumanogoh A, Kijima N, Kishima H, Sugiyama H.
Twenty-year persistence of WT1-specific cytotoxic T lymphocytes in peritumoral brain tissue by peptide vaccine therapy: Transcriptomic evidence for resident memory T-cell induction.
Neurooncol Adv. 2026 Jul 9;8(1):vdag176. doi: 10.1093/noajnl/vdag176. PMID: 42494995. ˍ